Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years old (including those who are exactly 18 or 80)
• People who understand what the study involves and are willing to sign a consent form
• People who have been confirmed by tissue or cell testing to have advanced or spreading stomach cancer or cancer at the junction of the stomach and oesophagus that cannot be removed by surgery, is HER-2 negative, and is a specific type called adenocarcinoma
• People who have at least one tumour that can be measured on scans, according to standard measurement guidelines
• People who have not previously received any anti-cancer treatment
• People with a physical fitness score of 0 or 1 on a standard scale used by cancer researchers (meaning fully active or able to carry out light work)
• People with an expected survival of at least 3 months
• People whose blood, liver, kidney, and clotting test results fall within the required ranges in the 7 days before joining (confirm with trial site for specific values)
• Women of childbearing age who have a negative pregnancy test within 3 days before the first dose of the study treatment
• People who agree to use an approved form of contraception (such as an IUD, contraceptive pill, or condom) during the study and for 6 months after treatment ends — this applies to participants and their sexual partners

Who may not be able to join:

• People who are currently in another interventional clinical study, or who have received another experimental drug or device within the 4 weeks before the first dose
• People who have used certain Chinese herbal medicines with anti-cancer or immune-modifying properties within 2 weeks before the first dose, or who have had major surgery within 3 weeks before the first dose
• People with severe heart failure (Class III–IV) or poorly controlled, clinically significant irregular heartbeat
• People who have had a heart attack, unstable chest pain, stroke, or mini-stroke within the 6 months before starting treatment
• People with a known allergy to any of the drugs used in this study
• People who need long-term daily steroid tablets or injections (people with lung conditions such as asthma or COPD who only use inhalers or intermittent steroids may still be considered)
• People with brain or spinal cord metastases causing symptoms — people with symptom-free brain metastases, or those whose symptoms have been stable after treatment for at least 2 weeks, with no spread to certain specific brain regions, and with at least one measurable lesion outside the brain, may be considered (confirm with trial site)
• People who have not stopped hormone therapy at least 3 days before the first dose
• People with an active infection currently needing treatment, or who have used systemic antibiotics or antifungals in the week before the first dose
• People who have not yet recovered from side effects of a previous treatment (side effects must be at mild level or back to baseline, except for tiredness or hair loss)
• People with a known diagnosis of HIV (positive for HIV 1/2 antibodies)
• People with untreated active hepatitis B, where the virus is detectable above the laboratory's normal limit
• People with active hepatitis C, where the virus is detectable in the blood
• People who are pregnant or breastfeeding
• People with other medical conditions, abnormal test results, or circumstances that the trial doctor considers would make participation unsuitable or unsafe (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.